Last Price | 2.37 | Max Price | 2.53 |
Min Price | 1.85 | 1 Year return | 50.96 |
Sector | Health Care | Subsector | Pharmaceuticals |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 10 | 615,670 | 0.00 % |
2020 | 7 | 638,104 | 0.00 % |
2021 | 9 | 727,997 | 0.00 % |
2022 | 11 | 787,317 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The stock lost over the past 12 months at around 0 percent. Over the period from December 2011 till December 2016 the stock rose on average 158 percent. Biohit's revenues between 2011 and 2015 were very volatile through the time and moved between 2,05 million euros and 6,05 million euros. Biohit's net results between 2011 and 2015 were very fluctuating and moved between -9,69 million euros and -2,92 million euros.
Over the past 10 years the global pharmaceutical companies gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
Over the past 5 years the Finnish company paid out dividends. On average Biohit's dividend yield over the past 5 years was around 1,42 percent annually.
The Finnish company had ultimo 2015 approximately 4715 thousand employees on it's payroll.
Last year the balance sheet of the Finnish company was worth 11,73 million euros. Last year the total debt of the company was 1,42 million euros. This equals around 12,11 percent of the total balance sheet.
At the end of 2015 the Finnish company had around 14,28 million stocks listed.
All the annual reports of Biohit are available here. More information about Biohit can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
6
|
8
|
9
|
10
|
10
|
7
|
Costs |
9
|
12
|
3
|
12
|
11
|
10
|
Profit |
-3
|
-3
|
6
|
-2
|
-1
|
-3
|
Margin of profit |
-48.26
|
-40.24
|
68.37
|
-21.55
|
-14.13
|
-46.49
|
ROI |
-28.32
|
-30.70
|
35.61
|
-13.47
|
-9.74
|
-38.05
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
10
|
11
|
17
|
16
|
15
|
9
|
Debt |
1
|
2
|
2
|
2
|
3
|
2
|
Total assets |
12
|
13
|
19
|
18
|
17
|
11
|
Solvency |
87.89
|
82.76
|
91.22
|
88.82
|
83.94
|
80.71
|
Cash |
7
|
8
|
9
|
9
|
9
|
6
|
Cashflow |
-3
|
-2
|
-1
|
0
|
0
|
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-2.22
|
-1.10
|
-0.57
|
-0.04
|
0.03
|
-0.01
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
5.61
|
6.05
|
3.77
|
2.96
|
3.36
|
Eps |
-0.22
|
0.41
|
-0.14
|
-0.09
|
-0.22
|
Price/earnings-ratio |
-25.50
|
14.76
|
-26.93
|
-32.89
|
-10.77
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
0.92
|
1.45
|
1.33
|
1.21
|
0.72
|
Market to book |
0.16
|
0.24
|
0.35
|
0.41
|
0.30
|
Cashflow per stock |
-0.21
|
-0.08
|
-0.01
|
0.01
|
|
Stocks |
12
|
12
|
12
|
12
|
12
|
Market Cap |
65.77
|
72.06
|
45.15
|
35.73
|
28.61
|
Date
|
Price
|
---|---|
13 Nov 2024
|
2.37
|
08 Nov 2024
|
2.46
|
05 Nov 2024
|
2.35
|
31 Oct 2024
|
2.43
|
29 Oct 2024
|
2.50
|
23 Oct 2024
|
2.53
|
19 Oct 2024
|
2.35
|
16 Oct 2024
|
2.35
|
14 Oct 2024
|
2.35
|
05 Oct 2024
|
2.27
|
02 Oct 2024
|
2.27
|
27 Sep 2024
|
2.16
|
20 Sep 2024
|
2.17
|
17 Sep 2024
|
2.15
|
13 Sep 2024
|
2.15
|
28 Aug 2024
|
2.11
|
26 Aug 2024
|
2.18
|
23 Aug 2024
|
2.14
|
11 Aug 2024
|
2.23
|
07 Aug 2024
|
2.29
|
05 Aug 2024
|
2.38
|
01 Aug 2024
|
2.37
|
30 Jul 2024
|
2.34
|
26 Jul 2024
|
2.30
|
23 Jul 2024
|
2.13
|
16 Jul 2024
|
2.21
|
10 Jul 2024
|
2.05
|
09 Jul 2024
|
2.07
|
04 Jul 2024
|
2.03
|
02 Jul 2024
|
1.99
|